Evidence map›Paper›PMID 34864822›Full record

ArticleCell death & disease2021

Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p/FOXM1 axis.

Yongming Jiang, Hui Zhao, Yuxiao Chen, Kangjian Li, Tianjie Li, Jianheng Chen, Baiyu Zhang, Caifen Guo, Liangliang Qing, Jihong Shen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Long noncoding HOXD-AS1: a crucial regulator of malignancy.Frontiers in cell and developmental biology · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yongming Jiang *Department of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Hui Zhao *Department of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.ORCID http://orcid.org/0000-0002-8881-6818
Yuxiao Chen *Department of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Kangjian LiDepartment of Urology, The Second People's Hospital of Qujing City, Qujing City, Yunnan Province, 655000, China.
Tianjie LiDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Jianheng ChenDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Baiyu ZhangDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Caifen GuoDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Liangliang QingDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Jihong ShenDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Xiaodong LiuDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China. liuxd@ydyy.cn.ORCID http://orcid.org/0000-0001-6788-8129
Peng GuDepartment of Urology, The 1st Affiliated Hospital of Kunming Medical University, Kunming, 650032, China. gupeng@ydyy.cn.ORCID http://orcid.org/0000-0002-9646-172X
Kunming Medical University · CNSecond People's Hospital of Yunnan Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of distant metastasis is the main cause of deaths in prostate cancer (PCa) patients. Understanding the mechanism of PCa metastasis is of utmost importance to improve its prognosis. The role of exosomal long noncoding RNA (lncRNA) has been reported not yet fully understood in the metastasis of PCa. Here, we discovered an exosomal lncRNA HOXD-AS1 is upregulated in castration resistant prostate cancer (CRPC) cell line derived exosomes and serum exosomes from metastatic PCa patients, which correlated with its tissue expression. Further investigation confirmed exosomal HOXD-AS1 promotes prostate cancer cell metastasis in vitro and in vivo by inducing metastasis associated phenotype. Mechanistically exosomal HOXD-AS1 was internalized directly by PCa cells, acting as competing endogenous RNA (ceRNA) to modulate the miR-361-5p/FOXM1 axis, therefore promoting PCa metastasis. In addition, we found that serum exosomal HOXD-AS1 was upregulated in metastatic PCa patients, especially those with high volume disease. And it is correlated closely with Gleason Score, distant and nodal metastasis, Prostatic specific antigen (PSA) recurrence free survival, and progression free survival (PFS). This sheds a new insight into the regulation of PCa distant metastasis by exosomal HOXD-AS1 mediated miR-361-5p/FOXM1 axis, and provided a promising liquid biopsy biomarker to guide the detection and treatment of metastatic PCa.

Indexed as

MicroRNAsProstatic NeoplasmsCell Line, TumorCell MovementCell ProliferationForkhead Box Protein M1Gene Expression Regulation, NeoplasticHumansMaleRNA, Long NoncodingForkhead Box Protein M1FOXM1 protein, humanlong non-coding RNA HOXD-AS1, humanMicroRNAsMIRN361 microRNA, humanRNA, Long Noncoding

Identifiers

PMID34864822
PMCPMC8643358
OpenAlexW4225773254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.